Background: High-density lipoprotein (HDL) has been shown to inhibit leukocyte adhesion to endothelial cells induced by endotoxin in vivo and suppress the growth of bacteria in vitro; however, the components responsible for these effects, either lipids or proteins, are not yet defined. In this study, we examined the effects of apolipoprotein (apo) A-I, the major protein of HDL, on ameliorating the effect of endotoxin and inhibiting the growth of bacteria. Materials and Methods: Apo A-I, purified from normal human HDL, was incubated with endotoxin. Leukocyte adhesion to endothelial cells of rat mesenteric venules was assessed using intravital fluorescence microscopy. Ability of apo A-I to inhibit the growth of Escherichia coli was assessed using a spread plate method. Results: Purified, lipid-free apo A-I could inhibit endotoxin-induced leukocyte adhesion to endothelial cells in vivo in a dose-dependent manner. In addition, apoA-I was able to suppress the growth of Escherichia coli in vitro. Conclusions: These data suggest that apo A-I of HDL can directly interact with endotoxin, ameliorating its effect and that apo A-I may have a direct toxic effect on whole bacteria. Therefore, therapeutic use of apo A-I in septicemia and bacterial infection should be further explored.
INTRODUCTION
Lipoproteins have been well recognised as playing an important role in the pathogenesis of atherosclerosis. A high level of low-density lipoprotein (LDL) cholesterol is a major risk factor for atherosclerosis, while high-density lipoprotein (HDL) can protect against atherosclerosis. There is growing, recent evidence that lipoproteins are part of innate immunity, protecting against the deleterious effect of infection and inflammation. 1 Several types of lipoproteins have been shown to bind and neutralize the effects of endotoxin (lipopolysaccharide, LPS) from Gram-negative bacteria. [2] [3] [4] [5] [6] When endotoxin was added to normal human whole blood in vitro, the majority of endotoxin was detected in HDL. 7 In vivo, mice with high levels of HDL are resistant to LPS-induced death and severe Gram-negative bacterial infections. 8 In humans, reconstituted HDL decreases flu-like symptoms and cytokine release during experimental endotoxemia. 9 Taken together, these studies provide strong evidence that lipoproteins, especially HDL, play a vital role in host defense during endotoxemia. Although a variety of biophysical experiments have shown that the functional groups of endotoxin interacting with HDL are the phosphates and the diglucosamine backbones, 10 it is still not clear which part(s) of HDL, lipid or protein, interacts with LPS.
Certain proteins associated with HDL have been demonstrated to bind and help modulate the inactivation of endotoxin. Apolipoprotein (apo) A-I, the major apolipoprotein of HDL, for example, can bind endotoxin and decrease cytokine production of macrophages induced by endotoxin. 11, 12 Endotoxin pre-incubated with apoA-I in vitro also reduces the febrile response in animals. 5 Similarly, apoA-IV can reduce secretion of cytokines by macrophages. 13 Administration of apoE can decrease death induced by endotoxin in mice. 14 Another HDL-associated protein that binds endotoxin and neutralizes its toxic effect is lipopolysaccharide-binding protein (LBP). 15, 16 We have previously shown that HDL can inhibit leukocyte adhesion to endothelial cells induced by endotoxin in rats.(Thaveeratitham et al., manuscript in press). In addition, another study has found that HDL can suppress the growth of bacteria. 17 Therefore, in this study, we examined the effects of apoA-I, the major protein of HDL, in ameliorating the effect of endotoxin and in inhibiting the growth of bacteria. We showed that purified, lipid-free apoA-I could inhibit endotoxin-induced leukocyte adhesion to endothelial cells in vivo and suppress the growth of Escherichia coli in vitro. These data suggest that apoA-I of HDL can directly interact with endotoxin, ameliorating its effect and that apoA-I may have a direct toxic effect on whole bacteria.
MATERIALS AND METHODS

Materials
Lipopolysaccharide (LPS from E. coli serotype O55:B5), supplied as gel filtration purified LPS, was purchased from Sigma (St Louis, MO, USA). The amount of protein contamination in the LPS preparation was < 2%. Ultrafree centrifugal devices and 0.22 µm pore size filter units were purchased from Millipore (Bedford, MA, USA). Various chemical supplies were purchased from Sigma or Asia Pacific Specialty Chemicals (Seven Hills, Australia). E. coli (ATCC 25922) was obtained from the Ministry of Public Health (Bangkok, Thailand). Liquid media and agar media were purchased from Oxoid (Hampshire, UK) and Sanofi (Paris, France).
Purification of human apoA-I
Human HDL from normal healthy volunteers isolated by ultracentrifugation was electrophoresed in polyacrylamide gels and apoA-I bands identified by copper staining were cut and eluted using an electro-eluter (Bio-Rad, Hercules, CA, USA) as previously described. 18 Purified apoA-I was dialyzed in 0.9% normal saline solution and filter sterilized. The protein concentration was determined using a modified Lowry method (Pierce).
Animal experiments
Male Wistar rats (200-300 g) were obtained from the National Animal Center, Mahidol University, Thailand. They were maintained on standard laboratory chow and tap water ad libitum for 5-7 days before experiments. The animal procedures were approved by the Ethics Committee of the Faculty of Pharmaceutical Sciences, Chulalongkorn University.
Assessment of leukocyte adhesion on endothelial cells of the mesentery
The method has been previously described. 19 Briefly, rats were anesthetized with sodium pentobarbital (60 mg/kg body weight) after an overnight fast. The carotid artery and the jugular vein were cannulated for measuring mean arterial pressure and for agent administration, respectively. A midline laparotomy was made and a loop of mesentery was exteriorized and spread onto a Plexiglass chamber for microscopic observation. The mesentery was fixed and superfused continuously with Krebs' Ringer solution. A postcapillary venule was chosen for observation under a fluorescence microscope (Nikon, Japan) equipped with a videocamera, a videorecorder, and a videotimer. Acridine orange was intravenously injected as a bolus through the cannulated jugular vein. After 20 min, baseline quantification of leukocyte adhesion was recorded. Leukocytes remaining stationary for 30 s on endothelial cells of the post-capillary venules were counted and expressed as number of cells per 100 µm vessel length. Endotoxin (0.1 µg/100 g body weight) was then administered and leukocyte adhesion was recorded at time zero and at later time points. In some studies, endotoxin was pre-incubated with purified human apoA-I at 37°C for 3 h before administration.
Bacterial culture and growth condition E. coli obtained from the Ministry of Public Health, Thailand was cultured in liquid media and subsequently resuspended in the same media with glycerol for storage at -80°C for long-term use. In each experiment, a pure bacterial strain from the glycerol stock was streaked on an agar plate and 3-4 colonies were subcultured in liquid media and incubated in a shaking incubator at 37°C until the log phase of bacterial growth cycle was obtained. Bacteria during the log phase were used in the study by dilution in liquid media to the desired concentration. Various concentrations of apoA-I were mixed with bacteria in liquid media (5000 colony-forming unit [cfu]/ml) and incubated in a shaking incubator at 37°C. At different time points, an aliquot was aspirated for plating on agar media in duplicate or triplicate. The number of colonies was counted and expressed as a percentage of control (no apoA-I).
Statistical analysis
The results are presented as mean ± SEM. Data on the effect of the various concentration of apoA-I on leukocyte adhesion induced by LPS were analyzed using a two-way ANOVA and the differences in pairs of the means among groups were performed using Tukey test. Data on the effect of the various concentration of apoA-I on bacterial growth were determined by a two-tailed Student's t-test. A P value of less than 0.05 was considered statistically significant.
RESULTS
Effect of human apoA-I on LPS-induced leukocyte adhesion on endothelial cells
Our previous study has shown that pre-incubation of endotoxin with HDL resulted in inhibition of endotoxin-induced leukocyte adhesion on endothelial cells. In this study, we examined whether lipid-free apoA-I accounts for the inhibitory effect on endotoxin. We found that pre-incubation of purified human apoA-I with endotoxin led to a decrease in endotoxin-induced leukocyte adhesion on endothelial cells in a dose-dependent manner (Fig. 1) . A 50% inhibition of leukocyte adhesion was achieved with about 4 µg of apoA-I/0.1 µg of endotoxin/100 g body weight.
Because apoA-I itself might affect leukocyte adhesion on endothelial cells, we administered apoA-I into the rats. We found that apoA-I alone had no effect on leukocyte adhesion on endothelial cells (data not shown).
In addition, the inhibitory effect of apoA-I on endotoxin-induced leukocyte adhesion requires incubation with endotoxin. When apoA-I was immediately mixed with endotoxin without incubation and administered, we found that apoA-I did not inhibit endotoxin-induced leukocyte adhesion (Fig. 2) .
60 Thaveeratitham, Plengpanich, Naen-Udorn, Patumraj, Khovidhunkit Fig. 1 . The effect of apoA-I on endotoxin-induced leukocyte adhesion on endothelial cells of the rat mesentery. Various concentrations of apoA-I were preincubated with endotoxin (0.1 µg/100 g body weight) before administration to rats and the amount of leukocyte adhesion on endothelial cells was quantified as described in Materials and Methods. n = 5-6 in each group; *P < 0.05, significant difference from the endotoxin group.
Effect of human apoA-I on the growth of E. coli
Beside the effect of HDL on endotoxin-induced leukocyte adhesion, HDL has been demonstrated to inhibit the growth of bacteria in vitro. To determine whether apoA-I could suppress the growth of bacteria, purified human apoA-I was incubated with E. coli and the bacterial growth was assessed at different time points. Apo A-I at the concentration of 100 µg/ml was able to inhibit significantly the growth of E. coli, as shown in Figure 3 . Apo A-I rapidly inhibited the growth at 3 h and produced a maximal effect on E. coli growth (a 50% inhibition) at 6 h. The growth continued to be significantly suppressed 21 h after incubation.
The dose-response curve of the apoA-I effect on the growth of E. coli was examined at the 6-h time point. Incubation of apoA-I with E. coli resulted in a dosedependent inhibition of the growth of E. coli (Fig. 4) . The half maximal concentration for inhibition was about 35 µg/ml. The concentrations of apoA-I used in this experiment are within the physiological range of the apoA-I concentration found in interstitial fluid (~150 µg/ml), 20 which is about 10 times lower than the concentration of apoA-I found in the plasma. 21 
DISCUSSION
HDL is a group of lipoproteins known to have anti-atherogenic effects by its ability to remove excess cholesterol from cells and transport it to the liver for excretion as well as its effect on protecting against LDL oxidation. Less known, however, is the role of HDL in innate immunity. When endotoxin was added to human whole blood, the majority (60%) of endotoxin was detected in HDL. 7 Binding of endotoxin to HDL ameliorates its toxic effects in vitro. 2, 6 In animals, infusion of reconstituted HDL protects against endotoxic shock and Gram-negative bacteremia. 22, 23 Transgenic mice overexpressing apoA-I, which have high HDL levels, are also resistant to endotoxininduced lethality and Gram-negative infection. 8 The beneficial effect of HDL as part of host defense during endotoxemia has been attributed to the binding and inactivation of endotoxin by HDL, although the nature of this interaction is not completely understood. The functional groups of endotoxin that interact with HDL were identified as the phosphates and the diglucosamine part of lipid A. 10 However, conflicting evidence exists regarding the necessary component(s) of lipoproteins (lipid versus protein) that attenuates the toxic Apo A-I on leukocyte adhesion to endothelial cells and growth of E. coli 61 Fig. 2 . The effect of incubation between endotoxin and apoA-I on LPS-induced leukocyte adhesion on endothelial cells of the rat mesentery. Endotoxin (0.1 µg/100 g body weight) was or was not pre-incubated with apoA-I before administration to rats and the amount of leukocyte adhesion on endothelial cells was quantified as described in Materials and Methods. n = 5-6 in each group; *P < 0.05, significant difference from the endotoxin group. effects of endotoxin. Some studies using triglyceride-rich lipid emulsion, which lacks proteins, demonstrated endotoxin-neutralizing effect similar to lipoproteins, 4 suggesting that the protein component of lipoproteins is not necessary. On the other hand, certain HDL-associated proteins can bind and help modulate the inactivation of endotoxin by HDL. 24 LBP, for example, has also been shown to bind endotoxin and protects animals against endotoxin-induced mortality. 16, 25 Apo A-I, a major HDL-associated protein, also binds endotoxin and decreases the activation of macrophages induced by endotoxin. 11, 12 Endotoxin preincubated with apoA-I in vitro has been demonstrated to decrease the febrile response and mortality in animals. 5, 11 Although both LBP and apoA-I exert similar effects on endotoxin, it is difficult to compare the effects of LBP with those of apoA-I because methods used in those 62 Thaveeratitham, Plengpanich, Naen-Udorn, Patumraj, Khovidhunkit studies were different. Tobias et al. 25 has shown that purified LBP could bind Salmonella enterica sv. Minnesota Re595 LPS in a concentration-dependent manner. For apoA-I, however, no dose response curve has been performed. Ma et al. 11 showed that apoA-I coated on a 96-well plate could bind fluorescencelabeled E. coli LPS (FITC-LPS, 2 × 10 4 g/l), which gave a higher number of fluorescent strength than phosphatebuffered saline (PBS). Both LBP and apoA-I have also been shown to protect animals against LPS-induced mortality, and the concentration of apoA-I required to exert the effect appears to be higher than that of LBP. However, the concentrations of LPS used in these studies were also different. When 2.5 ng of LPS (from E. coli O11:B4) was given to D-galactosamine-sensitized mice, 75% survival rate at 24 h was observed in mice receiving 100 µg of recombinant LBP. 16 In human apoA-I transgenic mice injected with 30 mg/kg of LPS (from E. coli 0111:B4), ~50% survival rate at 24 h was observed; the mice had plasma human apoA-I concentrations around 389 mg/dl. 8 Previously, we have shown that pre-incubation of endotoxin with human HDL resulted in inhibition of endotoxin-induced leukocyte adhesion on endothelial cells of the rat mesentery.(Thaveeratitham et al., manuscript in press); however, the protein-free lipid component of HDL had no effect. In this study, we further showed that purified human apoA-I exerted similar effects, suggesting that it was the apoA-I protein of HDL that interacted with endotoxin. Structural analysis of apo A-I indicates that it has several amphipathic αhelices. One or more of these helices, therefore, may bind and shelter lipid A of endotoxin, ameliorating its toxic effects. Recently, an apoA-I mimetic peptide, which forms an amphipathic helix, has been shown to inhibit endotoxin-induced inflammatory responses whereas a control peptide had no effect. 26 Although the interaction between HDL and endotoxin has been extensively studied, the effect of HDL on intact bacteria has received little attention. Apo A-I transgenic mice, which had high levels of HDL, were resistant to severe Gram-negative bacterial infections. 8 Reconstituted HDL also protected rabbits against Gram-negative bacteremia. 27 These beneficial effects of HDL were attributed to its interaction with endotoxin, although HDL might have the direct effect on bacteria. In vitro, HDL has been shown to inhibit the growth of bacteria. 17 We, therefore, tested whether apoA-I, the major protein component of HDL, had similar effects. In this study, we demonstrated that apoA-I can inhibit the growth of Gram-negative E. coli in vitro in a dose-dependent manner. Whether human apoA-I has effects on other Gramnegative bacteria is also currently unknown, but it has been reported that human apoA-I could inhibit the growth of Gram-positive Staphylococcus epidermidis. 17 In addition, carp apoA-I was found to suppress the growth of Gram-neg-ative fish bacteria, Pseudomonas spp. and Yersinia ruckeri. 28 Our findings suggested that apoA-I could have important clinical implications during bacteremia. It is known that the concentrations of apoA-I decrease during infection and low levels of apoA-I and HDL are associated with poor prognosis in patients with sepsis. 29 Whether replenishing apoA-I in the circulation during bacteremia could decrease morbidity and/or mortality remains to be seen. The mechanism by which apoA-I inhibits the growth of bacteria is also currently unknown. There is a report, however, suggesting that apoA-I can bind a specific protein of certain bacteria, such as group A Streptococci. 30 Recently, another HDL-associated protein, apoL-I, has been shown to be toxic to parasitic trypanosomes. By forming anion channels in the lipid bilayer of lysosomes, apoL-I causes depolarization of the membrane, resulting in osmotic swelling and lysis of these parasites. 31 The use of apoA-I therapeutically has been investigated in humans. Intravenous infusions of purified apoA-I or pro-apoA-I phospholipid complex resulted in no adverse events. 32, 33 Recently, recombinant apoA-I Milano-phospholipid complexes have been used in patients with acute coronary syndromes. 34 Apo A-I Milano is a variant form of apoA-I, which exhibits anti-atherosclerotic effects in animals. When these complexes were administered in patients with acute coronary syndromes, significant regression of coronary atherosclerotic plaques were demonstrated. While these clinical trials suggest that apoA-I is a potential therapeutic target in treatment of atherosclerosis, it may also have important functions in the defense mechanism against endotoxemia and infection. The results from our present study suggest that the therapeutic use of apoA-I in septicemia and bacterial infection should be further explored.
